君实生物-B(01877.HK)拟认购Anwita约299.02万股A系列优先股
格隆汇6月24日丨君实生物-B(01877.HK)公告,上海君实生物医药科技股份有限公司与Anwita Biosciences, Inc.签署《股份购买协议》和《许可协议》。根据《股份购买协议》约定,公司同意认购Anwita的299.02万股A系列优先股,约占其发行在外股份的20%,对价为1000万美元。
根据《许可协议》约定,公司以于大中华区(包括中国内地、台湾、澳门及香港)开发及商业化Anwita的创新IL-21融合蛋白(项目代号“AWT008”)。考虑到Anwita授予许可,公司同意在签署《许可协议》并完成AWT008的技术转让后向Anwita支付合共200万美元。此外,根据《许可协议》,若AWT008符合提交IND的要求,本公司可批准继续提交IND并进行随后的临床试验以就其商业化销售获得监管许可。在此情况下,Anwita将有权就AWT008计划的开发里程碑中收取合共最高6450万美元。
IL-21为一种活性细胞因子,可刺激先天性和适应性免疫细胞的激活,如自然杀伤(NK)细胞及细胞毒性T细胞。AWT008为Anwita专有的IL-21融合蛋白,由于其作用机制,其于动物模型中具有延长的半衰期及改善的体内抗肿瘤活性,且旨在作为单一药物或与其他治疗药物合并开发。
Anwita是一家总部位于旧金山湾区的公司,专注于创新蛋白质工程,以产生用于免疫肿瘤学(IO)的同类最优细胞因子。Anwita与公司不存在关联关系。
协议签署将进一步深化双方在大分子生物药的国际研发合作,丰富公司药物的研发管线,进一步对公司的全球化发展产生积极影响。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.